Annual Report 201325 Apr 2014 14:47
The Group has continued to increase its share
of the preclinical market and made important
strategic progress including expansion of its
product sets and entry into the early phase
clinical market. The increase in new SaaS deals
signed in the year is particularly pleasing. Our
SaaS offer is compelling for clients and provides
the Group with increasing long-term revenue
visibility.
Instem, like other pharmaceutical services
companies, is beginning to see an improvement
in its end markets, with the global
pharmaceutical market re-focusing its efforts
into early stage development work. In addition,
the industry’s regulatory and fiscal pressures
continue to work in Instem’s favour, driving
demand for all areas of our product portfolio.
With the benefit of a full year’s contribution
from both the Instem Clinical and more recent
Perceptive Instruments acquisitions, we look
forward to 2014 with confidence.
P J Reason,
Chief Executive
http://investors.instem.com/docs/instem-annual-report-2013.pdf